Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies

Nicole Schuitmaker

doi:10.33448/rsd-v12i9.43308

Autores

Nicole Schuitmaker University of Johannesburg https://orcid.org/0000-0002-2821-0419

DOI:

https://doi.org/10.33448/rsd-v12i9.43308

Palavras-chave:

Psilocibina; Cogumelo psicodélico; Terapia assistida por psilocibina; Revisão de escopo; Experiências; Pesquisa qualitativa.

Resumo

Houve um aumento na pesquisa sobre Terapia Assistida por Psilocibina (TAP) nas últimas três décadas. O TAP produziu resultados positivos em ensaios clínicos e demonstrou eficácia no tratamento de vários transtornos mentais. No entanto, existe uma investigação qualitativa limitada que explora as experiências das pessoas em matéria de TAP. Este estudo tem como objetivo revisar a literatura atual sobre as experiências de indivíduos que participaram do TAP, bem como de indivíduos que facilitaram o TAP. Este estudo visa aumentar nossa compreensão do TAP para orientar e melhorar a eficácia. Uma revisão de escopo foi conduzida a partir de estudos de língua inglesa publicados em periódicos revisados por pares. As pesquisas foram realizadas nas bases de dados PsycInfo, CINAHL, PubMed, Web of Science e Cochrane Library. Os critérios de inclusão foram estudos qualitativos envolvendo TAP realizados entre Janeiro de 1990 e Dezembro de 2022; artigos publicados em revistas especializadas; e experiências de praticantes psicodélicos de facilitação do TAP. No total, foram extraídos 13 artigos para inclusão na revisão. Os artigos foram publicados entre 2017 e 2021 e foram divididos em (1) Estudos de Participantes (10) e (2) Estudos de Facilitadores (3). Foram identificados seis temas: a influência do cenário e do cenário; O TAP foi personalizado e significativo; TAP pode ser altamente emotivo; experiências transcendentais; redução dos sintomas e alterações duradouras; e limites e responsabilidade. A literatura revelou numerosos elementos terapêuticos inter-relacionados que podem ter contribuído para uma experiência significativa durante o TAP. Isto pode desempenhar um papel na obtenção de resultados terapêuticos positivos duradouros. Os estudos foram variados e destacaram a utilidade de explorar mais o TAP.

Referências

Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2021). Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: An interpretive phenomenological analysis. Journal of Humanistic Psychology, 1-28. https://doi.org/10.1177/00221678211022949

Al-Naggar, R. A., Alshaikhli, H., & Erlam, G. (2021). Effectiveness of psilocybin on depression: A qualitative study. Electronic Journal of General Medicine, 18(3), 3–9. https://doi.org/10.29333/ejgm/10862

Arksey, H., & O’Malley, L. (2005). Scoping studies: Towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19–32. https://doi.org/10.1080/1364557032000119616

Barrett, F. S., Robbins, H., Smooke, D., Brown, J. L., & Griffiths, R. R. (2017). Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Frontiers in Psychology, 8, 1-12. https://doi.org/10.3389/fpsyg.2017.01238

Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., & Ross, S. (2017). Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis. Journal of Humanistic Psychology, 57(4), 354–388. https://doi.org/10.1177/0022167817706884

Bienemann, B., Ruschel, N. S., Campos, M. L., Negreiros, M. A., & Mograbi, D. C. (2020). Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. PLoS ONE, 15(2), 1–14. https://doi.org/10.1371/journal.pone.0229067

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/10.1177/0269881114565144

Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., & Mennenga, S. E. (2018). Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Frontiers in Pharmacology, 9(FEB), 1–7. https://doi.org/10.3389/fphar.2018.00100

Breeksema, J. J., Niemeijer, A., Krediet, E., Vermetten, E., & Schoevers, R. (2020). Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs. https://doi.org/10.1007/s40263-020-00748-y

Brennan, W., Jackson, M. A., MacLean, K., & Ponterotto, J. G. (2021). A qualitative exploration of relational ethical challenges and practices in psychedelic healing. Journal of Humanistic Psychology, September, 1-31. https://doi.org/10.1177/00221678211045265

Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399–408. https://doi.org/10.1007/s00213-017-4771-x

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7

Coleman, R., & Walker, M. (2017). Psychedelic psychotherapy: A user friendly guide to psychedelic drug-assisted psychotherapy. Transform Press. https://books.google.co.za/books?id=yjmhswEACAAJ

Dorsen, C., Palamar, J., & Shedlin, M. G. (2019). Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: An exploratory study. Addiction Research & Theory, 27(2), 68–75. https://doi.org/10.1080/16066359.2018.1455187

Fadiman, J. (2011). The psychedelic explorer’s guide: Safe, therapeutic and sacred journeys. Park Street Press.

Frecska, E. (2011). The risks and potential benefits of ayahuasca use from a psychopharmacological perspective. In B. C. Labate (Ed.). The Internationalization of Ayahuasca (151-165). Lit Verlag. https://doi.org/10.13140/RG.2.1.1939.9286

Goldsmith, M. N. (2010). Psychedelic healing: The promise of entheogens for psychotherapy and spiritual development. Healing Arts Press.

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstad, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116

Grof, S. (2008). Brief history of transpersonal psychology. International Journal of Transpersonal Studies, 27(1), 46–54. http://dx.doi.org/10.24972/ijts.2008.27.1.46

Grof S. (2008). LSD Psychotherapy: The Healing Potential of Psychedelic Medicine. Multidisciplinary Association for Psychedelic Studies.

Grof, S. (2019). The way of the psychonaut: Encyclopedia for inner journeys (Vol 1). Multidisciplinary Association for Psychedelic Studies.

Guthrie, L. (2021). A phenomenology of challenging psychedelic experiences: From relational trauma to relational healing (Doctoral dissertation, Duquesne University). ProQuest Dissertations and Theses.

Hayes, C., Wahba, M., & Watson, S. (2022). Will psilocybin lose its magic in the clinical setting? Therapeutic Advances in Psychopharmacology, 12, 1-9. https://doi.org/10.1177/20451253221090822

Johnson, M. W., & Griffiths, R. R. (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics,14(3), 734–740. https://doi.org/10.1007/s13311-017-0542-y

Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587

Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., & Carhart-Harris, R. (2018). The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology, 235(2), 505–519. https://doi.org/10.1007/s00213-017-4820-5

Lehto, R. H., Miller, M., & Sender, J. (2022). The role of psilocybin-assisted psychotherapy to support patients with cancer: A critical scoping review of the research. Journal of Holistic Nursing, 40(3), 265–280. https://doi.org/10.1177/08980101211039086

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ, 339, 1-10. https://doi.org/10.1136/bmj.b2700

Lutkajtis, A. (2021). Four individuals’ experiences during and following a psilocybin truffle retreat in the Netherlands. Journal of Psychedelic Studies, 5(1), 22–32. https://doi.org/10.1556/2054.2021.00162

Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S. K., Owens, L. T., Bossis, A. P., & Ross, S. (2018). Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Frontiers in Pharmacology, 9, 1-6. https://www.frontiersin.org/articles/10.3389/fphar.2018.00256

Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019). Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. Journal of Psychoactive Drugs, 51(2), 123–134. https://doi.org/10.1080/02791072.2019.1580804

McCartney, A. M., McGovern, H. T., & De Foe, A. (2022). Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions. Journal of Psychedelic Studies, 6(1), 10–22. https://doi.org/10.1556/2054.2022.00211

Meikle, S. E., Liknaitzky, P., Rossell, S. L., Ross, M., Strauss, N., Thomas, N., & Castle, D. J. (2020). Psilocybin-assisted therapy for depression: How do we advance the field? Australian & New Zealand Journal of Psychiatry, 54(3), 225–231. https://doi.org/10.1177/0004867419888575

Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735–1740. https://doi.org/10.4088/JCP.v67n1110

Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018). The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions. Frontiers in Pharmacology, 9, 1-13. https://doi.org/10.3389/fphar.2018.00132

Nielson, E. M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies, 2(2), 64–73. https://doi.org/10.1556/2054.2018.009

Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018). Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology, 32(7), 756–769. https://doi.org/10.1177/0269881118780612

Nutt, D. (2019). Psychedelic drugs - A new era in psychiatry? Dialogues in Clinical Neuroscience, 21(2), 139–147. https://doi.org/10.31887/DCNS.2019.21.2/dnutt

Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan — a web and mobile app for systematic reviews. Systematic Reviews, 5(210), 1-10 https://doi.org/10.1186/s13643-016-0384-4

Peters, M. D. J., Marnie, C., Tricco, A. C., Pollock, D., Munn, Z., Alexander, L., & Khalil, H. (2020). Updated methodological guidance for the conduct of scoping reviews. JBI Evidence Synthesis, 18(10), 2119–2126. https://doi.org/10.11124/JBIES-20-00167

Pollan, M. (2018). How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. Penguin Books.

Phelps, J., & Henry, J. (2021). Foundations for training psychedelic therapists. Springer. https://doi.org/10.1007/7854_2021_266

Radakovic, C., Radakovic, R., Peryer, G., & Geere, J. A. (2022). Psychedelics and mindfulness: A systematic review and meta-analysis. Journal of Psychedelic Studies, 6(2), 137–153. https://doi.org/10.1556/2054.2022.00218

Read, T., & Papaspyrou, M. (2021). Psychedelics and psychotherapy: The healing potential of expanded states. Park Street Press.

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512

Schultes, R. E., Hoffman, A., & Rätsch, C. (2001). Plants of the Gods: Their sacred, healing, and hallucinogenic powers. Healing Arts Press.

Shaw, L., Rea, K., Lachowsky, N. J., & Roth, E. A. (2022). Magic mushroom use: A qualitative interview study of post-trip impacts and strategies for optimizing experiences. Journal of Psychoactive Drugs, 1–8. https://doi.org/10.1080/02791072.2022.2054746

Shore, R. J., Ioudovski, P., McKeown, S., Dumont, E., & Goldie, C. (2019). Mapping psilocybin-assisted therapies: A scoping review. MedRxiv. https://doi.org/10.1101/2019.12.04.19013896

Smith, W. R., & Appelbaum, P. S. (2022). Novel ethical and policy issues in psychiatric uses of psychedelic substances. Neuropharmacology, 216, 1-5. https://doi.org/10.1016/j.neuropharm.2022.109165

Soler, J., Elices, M., Dominguez-Clavé, E., Pascual, J. C., Feilding, A., Navarro-Gil, M., & Riba, J. (2018). Four weekly ayahuasca sessions lead to increases in ‘acceptance’ capacities: A comparison study with a standard 8-week mindfulness training program. Frontiers in Pharmacology, 9(MAR), 1–8. https://doi.org/10.3389/fphar.2018.00224

Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., & Riba, J. (2016). Exploring the therapeutic potential of Ayahuasca: Acute intake increases mindfulness-related capacities. Psychopharmacology, 233(5), 823–829. https://doi.org/10.1007/s00213-015-4162-0

Stauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021). Psilocybin-assisted group therapy and attachment: Observed reduction in attachment anxiety and influences of attachment insecurity on the psilocybin experience. ACS Pharmacology and Translational Science, 4(2), 526–532. https://doi.org/10.1021/acsptsci.0c00169

Stokke, C., & Rodriguez, M. C. (2021). Spiritual awakening experiences: A phenomenological study in transpersonal psychology. Self & Society, 49(2), 9-25.

Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N., Terrana, S., Friedman, H. L., & Ross, S. (2017). Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. Journal of Humanistic Psychology, 57(5), 488–519. https://doi.org/10.1177/0022167817715966

Thal, S. B., Bright, S. J., Sharbanee, J. M., Wenge, T., & Skeffington, P. M. (2021). Current perspective on the therapeutic pre-set for substance-assisted psychotherapy. Frontiers in Psychology, 12(July), 1-16. https://doi.org/10.3389/fpsyg.2021.617224

Tricco, A. C., Lillie, E., Zarin, W., O’Brien, K. K., Colquhoun, H., Levac, D., & Straus, S. E. (2018). PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and explanation. Annals of Internal Medicine, 169(7), 467–473. https://doi.org/10.7326/M18-0850

Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology, 57(5), 520–564. https://doi.org/10.1177/0022167817709585

Watts, R. (2020). The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science, 15, 92-102. https://doi.org/10.1016/j.jcbs.2019.12.004

Wheeler, S., & Dyer, N. (2020). A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future. Psychology of Consciousness: Theory, Research, and Practice, 7, 1-39. http://dx.doi.org/10.1037/cns0000237

Ziff, S., Stern, B., Lewis, G., Majeed, M., & Gorantla, V. R. (2022). Analysis of psilocybin-assisted therapy in medicine: A narrative review. Cureus, 14(2), 1-12. https://doi.org/10.7759/cureus.21944

Terapia Assistida por Psilocibina: Uma revisão de escopo das experiências dos participantes e facilitadores em estudos qualitativos

Autores

DOI:

Palavras-chave:

Resumo

Referências

Downloads

Publicado

Como Citar

Edição

Seção

Licença

JOURNAL METRICS

Idioma

Enviar Submissão